Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), as one of the most promising targeted drug for new cancer therapeutics, is limited in clinical application by the evolution of resistance in many cancer cell lines, especially in malignant melanoma. Thus, it is urgently needed to ident...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Cao, Wenqiang, Li, Xiaoling, Zheng, Shanyuan, Zheng, Wenjie, Wong, Yum-shing, Chen, Tianfeng
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2014
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4202134/
https://ncbi.nlm.nih.gov/pubmed/25277183
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items